Price Action Don’t Lie: What’s Propelling Sangamo Biosciences, Inc. to Increase So Much?

Price Action Don't Lie: What's Propelling Sangamo Biosciences, Inc. to Increase So Much?

The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) is a huge mover today! About 317,201 shares traded hands. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has declined 35.08% since March 7, 2016 and is downtrending. It has underperformed by 42.67% the S&P500.
The move comes after 6 months positive chart setup for the $320.51M company. It was reported on Oct, 10 by Barchart.com. We have $10.88 PT which if reached, will make NASDAQ:SGMO worth $442.30M more.

Analysts await Sangamo Biosciences, Inc. (NASDAQ:SGMO) to report earnings on October, 26. They expect $-0.25 earnings per share, down 92.31% or $0.12 from last year’s $-0.13 per share. After $-0.38 actual earnings per share reported by Sangamo Biosciences, Inc. for the previous quarter, Wall Street now forecasts -34.21% EPS growth.

Sangamo Biosciences, Inc. (NASDAQ:SGMO) Ratings Coverage

Out of 7 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 5 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 71% are positive. Sangamo Biosciences has been the topic of 9 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, September 3 by JP Morgan. The rating was reinitiated by Jefferies on Friday, October 23 with “Buy”. The company was downgraded on Thursday, August 4 by Janney Capital. Wells Fargo initiated Sangamo Biosciences, Inc. (NASDAQ:SGMO) on Friday, December 4 with “Outperform” rating. Jefferies maintained the stock with “Buy” rating in Wednesday, September 2 report. The firm has “Buy” rating by Cowen & Co given on Friday, September 4. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) earned “Sell” rating by Zacks on Tuesday, September 8. JP Morgan maintained the stock with “Overweight” rating in Saturday, August 8 report. Wedbush maintained the shares of SGMO in a report on Wednesday, September 2 with “Buy” rating.

According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.”

Insitutional Activity: The institutional sentiment decreased to 0.81 in Q2 2016. Its down 0.57, from 1.38 in 2016Q1. The ratio dived, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
Royal Commercial Bank Of Canada owns 23,820 shares or 0% of their US portfolio. Alliancebernstein Limited Partnership has 91,341 shares for 0% of their US portfolio. Mpm Asset Mngmt Ltd holds 0.04% or 22,487 shares in its portfolio. Teacher Retirement System Of Texas owns 9,268 shares or 0% of their US portfolio. First Republic Investment Mgmt Incorporated holds 0% or 19,500 shares in its portfolio. Piermont Management has 0.23% invested in the company for 154,619 shares. Geode Mgmt Limited Liability Company accumulated 0% or 500,351 shares. Blackrock Ltd has invested 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Janney Montgomery Scott Lc accumulated 0% or 29,956 shares. Moreover, California State Teachers Retirement Sys has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 145,781 shares. Morgan Stanley accumulated 312,911 shares or 0% of the stock. Moreover, Blackrock Fund Advsr has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 2.71 million shares. Vigilant Mgmt Limited Liability Company has 5,000 shares for 0.01% of their US portfolio. Tocqueville Asset Mgmt L P has invested 0.02% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Washington Trust Comml Bank accumulated 3,000 shares or 0% of the stock.

More notable recent Sangamo Biosciences, Inc. (NASDAQ:SGMO) news were published by: Fool.com which released: “Why Sangamo Biosciences, Inc. Fell 29% Today” on August 04, 2016, also Prnewswire.com with their article: “Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And …” published on June 01, 2016, Prnewswire.com published: “Sangamo BioSciences Announces Second Quarter 2016 Conference Call and Webcast” on July 27, 2016. More interesting news about Sangamo Biosciences, Inc. (NASDAQ:SGMO) were released by: Prnewswire.com and their article: “Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX …” published on September 06, 2016 as well as Prnewswire.com‘s news article titled: “Sangamo BioSciences Announces FDA Clearance of Investigational New Drug …” with publication date: June 20, 2016.

SGMO Company Profile

Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment